Orgenesis

Orgenesis

United States
Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation. Beta cell replacement is one of the most promising approaches for treatment of Insulin Dependent Diabetes Mellitus (IDDM). Currently, pancreas islet transplantation is the only approved cell replacement technology and it's the best available treatment for diabetics. However, it's impractical because of a shortage of donor tissue and rejection rate by the patient' immune system. Orgenesis believes that converting the diabetic patients own tissue to insulin producing cells will overcome the problem of donor shortage. Moreover, since the diabetic patient serves as his/her own donor, there is no risk of transplant rejection. Orgenesis has manifested promising results in in-vitro and in-vivo studies using human liver tissues. Based on this significant discovery and these findings, Orgenesis has designed an efficient and clear work-plan to initiate clinical testing in the next few months allowing the company to launch phase I clinical trials following FDA guidelines followed by the launch of Phase II clinical trials within a year.
Founded date
01/01/2008
# of employees
101-250
Company type
For Profit

General & financials

Estimated revenue
$1M to $10M
# of funders
1
Founders
Sarah Ferber
Industry group
Biotechnology, Health Care, Science and Engineering

Founding

Top 5 investors
Boundary Holding, Governing Dynamics Venture Capital
# of funding runds
5
Last founding
Total funded
$29.315.000

See more companies

See full list
Amethyst Radiotherapy

Amethyst Radiotherapy

Estimated revenue
$1M to $10M
# of employees
51-100
Company type
For Profit
ZyVersa Therapeutics

ZyVersa Therapeutics

Estimated revenue
$1M to $10M
# of employees
11-50
Company type
For Profit
Droplette

Droplette

Estimated revenue
$1M to $10M
# of employees
11-50
Company type
For Profit
3Scan

3Scan

Estimated revenue
$1M to $10M
# of employees
11-50
Company type
For Profit
ICAgen

ICAgen

Estimated revenue
$10M to $50M
# of employees
11-50
Company type
For Profit
SEngine Precision Medicine

SEngine Precision Medicine

Estimated revenue
$1M to $10M
# of employees
11-50
Company type
For Profit
Symetrica

Symetrica

Estimated revenue
$1M to $10M
# of employees
11-50
Company type
For Profit
AngioChem

AngioChem

Estimated revenue
$1M to $10M
# of employees
11-50
Company type
For Profit

How to get access to the full list?

Duplicate this list

Get access to a comprehensive list of companies with their industries, location and contacts infos.

Prepare outreach

Drafting good emails makes you more likely to get get results.

Track & Follow

Keeping momentum by managing all your angel investors prospects in a pipeline with pre-set stages: "contacted", "replied", "in discussion" for ex. Follow-up tightly, close in time.

What is folk?

folk is a lightweight and easy-to-use CRM that you can leverage to build lists of contacts and manage your processes with these contacts.

How to get access to this list of companies?

You can simply duplicate the list. You will need to create a folk account in order to duplicate the list properly.

What can I do with the list after duplicating it? 

On folk, you can directly email these companies and manage them in a pipeline board.